Pomacel 2mg capsules |

Pomalidomide | Millionpharma
 DESCRIPTION

 Pomalidomide is sold under the brand name

Pomacel 2mg and it belongs to anti-neoplastic drugs
 Pomacel 2mg is doable as orally bioavailable
thalidomide derivative associated with numerous
therapeutic activities such as: immune modulatory,
anti-angiogenesis, anti-neoplastic.
 Pomacel 2mg combination with dexamethasone will
cause liver injury
 CLINICAL USE

 The primary indication of Pomacel 2mg is used in the

treatment of Multiple Myeloma condition.
 In this condition, Pomacel 2mg is used by combining
with dexamethasone.
 Pomacel 2mg capsules are applicable in;
 Previously the Patients treated with two treatment such
as proteasome inhibitor & Lenalidomide.
 Patients who are suffered with disease progression
condition
 Pomacel 2mg treatment should be followed within 60
days in patients who are concluded the last treatment.
 MECHANISM OF ACTION

 Pomacel 2mg capsules has three primary

pharmacological activities against cancer cells.
 Pomalidomide includes in the way cancer proliferation
and provoke the apoptosis of cancer cells.
 Pomalidomide enhance the T cell & natural killer cells
interceding immunity & inhibits the formation of pro
inflammatory cytokines from monocytes.
 Pomalidomide forbid the new cell formation. The
binding of Pomalidomide to active site of targeted cell
causes inhibition of ubiquitin ligase action.
 Pomacel 2mg Capsules

 Brand : Pomacel
 Ingredients : Pomalidomide
 Strength : 2mg
 Manufactured : Glenmark Pharma
 Package : 21 capsules
 PHARMACOKINETICS

 The time to high serum concentration of Pomalidomide is reaches between 2 to 3

hours.
 It should be administered with or without food. Hence No effect of food should be
produced;
 Volume of distribution of Pomalidomide is between 62 & 138L in steady state.
 The Pomalidomide distribution by 67% of serum level at after 4 hours of drug
intake.
 human plasma protein by bounding range of 12% & 44%.
 Hepatically mediated through CYP1A2, CYP3A4 is Pomalidomide is metabolized.
 Pomalidomide clearance value is 7 to 10L/hr.
 Doses are excreted via urine 73% & feces 15% respectively.
 Doses are excreted as an unchanged form via urine 2% & feces 8%.
 Pomalidomide half-life period is 9.5 hours.
 DOSAGE MANAGEMENT

 During multiple myeloma malignancies;

 The dosage recommendation of Pomacel 2mg is 4mg
should be administered as a single dose for 1 to 21
days of successive 28-day cycles.
 Pomacel is combined with dexamethasone with low
dose.
 Administrate Dexamethasone on day 1, 8, 15 & 22 of
each 28-day cycle.
 The prescribed dose of dexamethasone is 40mg
should be administered the patient having weight
about ≤ 75kg.
 DOSAGE MANAGEMENT

 The prescribed dose of dexamethasone is 20mg given for

patient’s weight Greater than 75kg
 Dosage alteration during hematological toxicities;
 Neutropenia;
 ANC <500/mcL: Pomacel treatment should be
postponed and check the CBC weekly.
 ANC ≥ 500/mcL: Pomacel therapy should be continued
by 3mg/day
 For each successive drop <500/mcL: Pomacel 2mg
should be postponed.
 ANC ≥ 500/mcL: Continue the Pomacel therapy with
1mg/day.
 Thrombocytopenia:

 Platelets count <25000/mcL: Pomacel therapy

should be postponed and check CBC
 Platelets count ≥50000/mcL: 3mg of Pomacel
should be taken daily
 With strong CYP1A2:
 Pomacel combined with CYP1A2 substrates causes
increasing the plasma concentration of
Pomalidomide and leads to elevate the risk of
Pomalidomide.
 In renal damaged patients;
 DOSAGE MANAGEMENT

 In severe renal impaired patients, the suggested dose of

Pomacel is 3mg per day.
 In hepatic impaired patients;
 The advised dose is 3mg/day & in severe condition, the
suggested dose is 2mg/day given for mild to moderate
patients.
 The most probable worsening condition of Pomacel 2mg
is;
 Venous & arterial thromboembolism
 Embryo fetal damage.
FOR MORE INFO

 CONTACT NO : +91-9940472902

 EMAIL : millionhealthpharmaceuticals@gmail.com

 WEBSITE URL : https://millionpharma.com/pomacel-

2mg.php